NFKB1 and acute lymphoblastic leukemia: For example, NF-κB can be activated in cells resistant to vincristine and daunorubicin and inhibit this transcription factor with BAY 11-7082, which blocks IκB degradation and resensitises murine T-ALL cells to these two chemotherapeutics [51].